We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$511M
AUM Growth
+$16.2M
Cap. Flow
+$33.5M
Cap. Flow %
6.56%
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
AFIB
Acutus Medical Inc
AFIB
+$22.8M
2
PCVX icon
Vaxcyte
PCVX
+$12.5M
3
TARA icon
Protara Therapeutics
TARA
+$8.12M
4
CRDF icon
Cardiff Oncology
CRDF
+$7.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.73M

Top Sells

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$10.6M
2
QURE icon
uniQure
QURE
+$8.55M
3
APTO
Aptose Biosciences, Inc.
APTO
+$7.38M
4
MTEM
Molecular Templates, Inc.
MTEM
+$6.83M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOMA
26
DELISTED
Xoma
XOMA
$8.57M 1.68%
455,000
+39,620
+10% +$743K
AVTX icon
27
Avalo Therapeutics
AVTX
$1.08B
$7.68M 1.5%
1,171
– –
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.43M 1.45%
114,350
– –
ADMS
29
DELISTED
Adamas Pharmaceuticals
ADMS
$6.13M 1.2%
1,487,800
+527,800
+55% +$2.04M
KYNB
30
Kyntra Bio
KYNB
$32.4M
$6.04M 1.18%
5,880
+40
+0.7% +$43K
TELA icon
31
TELA Bio
TELA
$29.2M
$5.99M 1.17%
362,074
+112,074
+45% +$1.57M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$5.86M 1.15%
470,203
+8,703
+2% +$109K
LITS
33
Lite Strategy Inc
LITS
$34M
$4.86M 0.95%
77,800
– –
FOCL
34
EDAP TMS S.A.
FOCL
$199M
$4.78M 0.94%
1,040,000
-838,500
-45% -$2.89M
CYTK icon
35
Cytokinetics
CYTK
$10.8B
$4.52M 0.88%
208,800
-94,250
-31% -$2.2M
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$9B
$3.76M 0.74%
240,000
-195,200
-45% -$2.98M
FULC icon
37
Fulcrum Therapeutics
FULC
$294M
$3.58M 0.7%
+452,000
New +$5.44M
LUMO
38
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.33M 0.65%
+240,892
New +$3.6M
KZR
39
DELISTED
Kezar Life Sciences
KZR
$3.28M 0.64%
+67,800
New +$3.24M
VSTM icon
40
Verastem
VSTM
$668M
$3.2M 0.63%
+183,333
New +$3.03M
CDTX
41
DELISTED
Cidara Therapeutics
CDTX
$2.77M 0.54%
48,533
– –
SYRE icon
42
Spyre Therapeutics
SYRE
$8.25B
$2.66M 0.52%
+15,000
New +$2.77M
NERV icon
43
Minerva Neurosciences
NERV
$245M
$2.44M 0.48%
+95,925
New +$2.59M
OM icon
44
Outset Medical
OM
$76.9M
$2.25M 0.44%
+3,000
New +$2.46M
EPIX
45
DELISTED
ESSA Pharma
EPIX
$1.87M 0.37%
271,350
+96,350
+55% +$654K
STRO icon
46
Sutro Biopharma
STRO
$353M
$1.47M 0.29%
+14,600
New +$1.38M
CFRX
47
DELISTED
ContraFect Corporation
CFRX
$1.19M 0.23%
+2,827
New +$1.28M
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$982K 0.19%
+100,000
New +$985K
AMRN
49
Amarin Corp
AMRN
$297M
$947K 0.19%
11,250
-11,500
-51% -$1.38M
XFOR icon
50
X4 Pharmaceuticals
XFOR
$419M
$508K 0.1%
+2,500
New +$599K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2020 Portfolio in Review

As of Q3 2020, Opaleye Management held 68 positions worth $511M, up 3.3% from $495M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management deployed $33.5M of net new capital in Q3 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was Acutus Medical Inc: 749,990 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $7.38M trimmed.

  • Opaleye Management's largest Q3 2020 buy was Acutus Medical Inc: 749,990 shares worth $22.4M.
  • Opaleye Management added most to Protara Therapeutics in Q3 2020, an estimated $8.12M increase.
  • Opaleye Management's biggest Q3 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $7.38M.
  • Opaleye Management fully exited Odonate Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $10.6M.
  • Opaleye Management's ten largest holdings make up 49% of its $511M portfolio in Q3 2020.
  • Opaleye Management opened 20 new positions and closed 13 in Q3 2020.
  • Opaleye Management's portfolio value rose 3.3% quarter-over-quarter to $511M.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.